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Background/aim: Sarcoidosis is a complex, multifactorial immune disorder with unknown etiology. A single nucleotide polymorphism
(G→A, rs2076530) in the butyrophilin-like 2 (BTNL2) gene results in a truncating protein formation. It has been previously reported that
this variation may be a risk factor for sarcoidosis in certain ethnic groups. This study was conducted to determine whether there is any
genetic predisposition for the BTNL2 rs2076530 polymorphism in the 329-bp region in Turkish patients with sarcoidosis.
Materials and methods: DNA samples were obtained from volunteers including 53 Turkish patients with sarcoidosis and 52 healthy
controls. Analysis of the 329-bp region was carried out by polymerase chain reaction and sequencing of genomic DNA.
Results: We did not find any genetic variation except the rs2076530 polymorphism in the 329-bp region. The AA genotype was
associated with an increased risk of sarcoidosis in a recessive model [P = 0.027, OR 2.56 (95% CI 1.02–6.49)], but it did not include a
risk for sarcoidosis in a dominant model (P = 0.885).
Conclusion: Our results emphasize the recessive characteristic of the rs2076530 polymorphism in Turkish patients with sarcoidosis. The
lack of any genetic variation except rs2076530 in the 329-bp region is another significant finding for Turkish patients.
Key words: BTNL2 gene, genetic predisposition, single nucleotide polymorphism, sarcoidosis

1. Introduction
Sarcoidosis is a multisystemic chronic inflammatory
disorder that can affect the lungs, eyes, liver, and lymph
nodes and is mainly characterized by accumulations of
noncaseating epithelioid granulomas (1,2). The disease has
a complex pathogenesis and the etiology still is unknown
(2).
However, the disease is currently thought to be activated
in genetically susceptible individuals as a consequence of
exposure to various environmental and occupational, as
well as infectious, agents. Following the first description of
2 German sisters with sarcoidosis, the studies examining
the familial clustering of the disease in various populations
have reported 2.7%–17% of index cases with another
affected family member (3–5).
According to the estimations of A Case-Control
Etiologic Study of Sarcoidosis, the familial relative risk
adjusted for age, sex, relative class, and shared environment
has been reported by Rossman and Kreider (6) and Buck
and McKusick (7), who confirmed the significantly
* Correspondence: mozdemir@ogu.edu.tr
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increased risk of disease among first- and second-degree
relatives of sarcoidosis patients. They also showed the
importance of racial differences in the familial aggregation
of sarcoidosis cases (6–8).
Family-based studies have shown an association for
both disease susceptibility and phenotype expression
between sarcoidosis and human leukocyte antigen (HLA).
Genome-wide linkage studies have pointed out that the
extended major histocompatibility (MHC) locus on
chromosome 6p was linked to susceptibility to sarcoidosis.
However, because of the linkage disequilibrium in MHC,
it is not clear whether the susceptibility to the disease is
directly determined by HLA genes or if the association is
resulting from other linked genes within this region. The
truncating single nucleotide polymorphism rs2076530
in exon 5 of the butyrophilin-like 2 (BTNL2) gene, a
member of the immunoglobulin superfamily localized
in close proximity of the HLA complex on chromosome
6p, has been implicated for the first time as a risk factor
for sarcoidosis susceptibility by Valentonyte et al. (9). This
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G/A transition causes an alternative splice site located 4
bases upstream of the wild-type donor site. The premature
truncation of protein disrupts the membrane localization
of the protein because of the lack of the C-terminal of the
IgC domain and transmembrane helix (9).
The BTNL2 gene, an immunoglobulin gene
superfamily member with 6 exons, is located in close
proximity to the HLA class 2 and class 3 regions which is
the most gene-dense, polymorphic region of the genome,
containing predominantly immunomodulating genes
(10). The protein encoded by the BTNL2 gene shares
considerable amino acid and domain structure homology
with the B7.1 receptor. The B7.1 receptor, a member of
the B7 costimulatory molecule family, plays an important
role in the interaction between B and T lymphocytes
(11). It can either inhibit or promote T cell responses,
depending on the receptor it joins (12). Further studies in
mouse models have shown that BTNL2 protein binds to
a receptor on activated T cells and functions to suppress
T cell proliferation (13). Therefore, the involvement of
the truncated BTNL2 protein seems to be important in
sarcoidosis immunopathogenesis.
The close proximity of the BTNL2 gene to HLA-DRB1
and HLA-DQB1, which both have known sarcoidosis
risk alleles, complicates association studies between
BTNL2 and sarcoidosis. Therefore, Rybicki et al. studied
increased haplotype diversity in the MHC class II region
in populations of African origin to differentiate specific
gene effects (8). They identified 10 single nucleotide
polymorphisms (SNPs) within a 490-bp region spanning
exon/intron 5 of the BTNL2 gene. They concluded that
although haplotype variation within this region was
significantly associated with sarcoidosis in all studied
populations, the significance was higher in the white
population. Subsequent studies reported conflicting
results in different populations (14).
Our aim was to verify the association between the
rs2076530 SNP and sarcoidosis in Turkish patients and
to identify population-specific SNPs associated with
sarcoidosis within the exon 5/intron 5 border.
2. Materials and methods
2.1. Subjects
The total subject group comprised 53 patients with
sarcoidosis and 52 healthy Turkish individuals recruited
from the Department of Chest Diseases of the Eskişehir
Osmangazi University Faculty of Medicine in Eskişehir,
Turkey. All patients fulfilled the criteria defined in
the ATS/ERS/WASOG Statement on Sarcoidosis (1).
Informed consent was obtained from all patients and
healthy controls in accordance with our protocol, which
was accepted by the Ethics Committee of the Eskişehir
Osmangazi University Faculty of Medicine. In terms of

ethnicity, the patients and the healthy controls were all
homogeneously Turkish.
2.2. Genotyping
Genomic DNA was isolated from the peripheral
leukocytes of the individuals using standard methods. The
primers used in the amplification of the 329-bp exon 5/
intron 5 region, including the rs2076530 polymorphism,
were F- 5’-CTGGAGAGCAGATGGCAGAGTAC-3’
and R- 5’-ATGACAGTTTCACACACTGGAGG-3’. The
polymerase chain reaction (PCR) was carried in a total
reaction volume of 50 µL with 25 µL of master mix and 10
ng/µL genomic DNA. The amplification protocol included
initial denaturation at 95 °C for 3 min, followed by 35 cycles
of denaturation at 95 °C for 30 s, annealing at 57 °C for 30
s, extension at 72 °C for 1 min, and final extension for 10
min. Quality control of PCR products was performed by
agarose-gel electrophoresis to confirm the amplification
sizes. Then, following the purification protocols, the PCR
products of the BTNL2 exon 5-intron 5 region including
the rs2076530 polymorphism were sequenced by DNA
cycle sequencing (Applied Biosystems 3130) using BigDye
Terminator chemistry according to the manufacturer’s
protocols. The genotype was determined by Sequence
Analysis 5.1 software. The genotype of each case was
compared in the BLAST database for identification of
sequence variation.
2.3. Statistical analysis
In the statistical analysis of allelic and genotypic
distributions, SPSS 15.0 for Windows (SPSS Inc., Chicago,
IL, USA) was used. BTNL2 variation frequencies in the
groups were compared using Pearson’s chi-square test.
Odds ratios (ORs) were calculated to estimate the relative
risk of sarcoidosis using logistic regression analysis. The
2-proportions test was used to analyze the frequencies of
BTNL2 genotype as a binary comparison.
3. Results
The sequenced 329-bp region of exon 5/intron 5 in each
patient and control was evaluated in the BLAST database.
The only detected variation in the sarcoidosis patients was
the rs2076530 polymorphism; no further difference in
the 329-bp region was detected. A statistically significant
difference (P = 0.034) was seen when the frequencies of
the GG, GA, and AA genotypes in the sarcoidosis group
(32.1%, 24.5%, and 43.4%, respectively) were compared
with the genotypes of the control group (30.7%, 46.2%, and
23.1%, respectively). The frequency of the AA genotype
was significantly increased in the sarcoidosis group (Table
1).
No statistically significant difference (P = 0.168) was
determined when the allele frequencies of sarcoidosis
patients (G = 44.3%, A = 55.7%,) were compared with
the controls (G = 53.8%, A= 46.2%) for the rs2076530
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Table 1. Genotype and allele frequencies of the BTNL2 rs2076530 polymorphism of sarcoidosis patients and
healthy controls.
Genotypes
Groups

N

Alleles

GG
N

GA
%

AA

N

%

N

G

A

%

N

%

N

%

Controls

52

16

30.7

24

46.2

12

23.1

56

53.8

48

46.2

Sarcoidosis patients

53

17

32.1

13

24.5

23

43.4

47

44.3

59

55.7

P = 0.034 , P = 0.166 , P = 0.234 , P = 0.009

P-value
a

a

b

c

d

P = 0.168

a

Pearson’s chi-square test for all groups, bGG vs. GA; cGG vs. AA; dGA vs. AA by using 2-proportions test.

polymorphism (Table 1). We found a statistically significant
difference between the frequencies of the BTNL2 genotypes
of the patients and the controls, and so we analyzed these
genotypes as a binary comparison. The frequency of the
GG genotype was not statistically important compared
with GA (P = 0.162) and AA (P = 0.230) genotypes.
However, a significant difference was found between the
frequencies of the GA and AA genotypes (P = 0.006).
According to the BTNL2 genotype distribution, the
risk of having sarcoidosis was calculated by the OR, and
results are shown Table 2. The AA genotype was associated
with an increased risk of sarcoidosis in a recessive model
[P = 0.027, OR 2.56 (95% confidence interval [CI]: 1.02–
6.49)] but was not associated with a risk in a dominant
model (P = 0.885).

of its homology with B7-1 (13). They reported the highest
expression of BTNL2 in mouse lymphoid tissues, as well
as intestines, and enhanced the expression of its putative
receptors on B and T cells. These expression analyses
showed that the BTNL2 molecule functions to inhibit T
cell activation, which has impacts in immune diseases
such as sarcoidosis. It is becoming more apparent that
the gene function of BTNL2 may play an important role
in the pathophysiology of sarcoidosis. The accumulation
of familial cases has also suggested that a genetic
predisposition to the disease exists (3–5).
In this study, we evaluated the SNP of the BTNL2
gene as a possible genetic risk factor for sarcoidosis in
a Turkish population. In the complete patient cohort,
BTNL2 rs2076530 was significantly associated with disease
risk. Many studies have been conducted in different
ethnic groups in terms of genetic predisposition, but
different clinical manifestations have been obtained. In
white and African American populations, Rybicki et al.
carried out family-based and case-control studies (8).
They reported the strongest association of rs2076530 SNP
with sarcoidosis. They also emphasized that the higher
association between the rs2076530A allele and sarcoidosis
was predominantly seen in the white population.
In another study, sarcoidosis patients and control
subjects were recruited from 2 European countries (14).
The A allele of BTNL2 was associated with an increased risk

4. Discussion
In the present study, we aimed to sequence the 329-bp
region of the BTNL2 gene including the rs2076530 SNP in
Turkish patients with sarcoidosis. In order to design our
study, the literature was retrospectively searched. The first
gene region to show genetic predisposition to sarcoidosis
was identified by Valentonyte et al., who searched a 16.4Mb locus on 16p21 and found a 15-kb section of BTNL2
associated with sarcoidosis in German patients (9).
Nguyen et al. published the first results of the BTNL2 gene
function, which is involved in T-cell activation on the basis

Table 2. Association of BTNL2 genotype with sarcoidosis susceptibility according to mode of
inheritance.

Groups

N

Controls

52

Sarcoidosis patients

53

P-value
*
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Pearson’s chi-square test.

Dominant model

Recessive model

AA/GA

GG

AA

N

%

N

%

N

%

N

%

36

69.23

16

30.77

12

23.08

40

76.92

36

67.93

17

32.07

23

43.40

30

56.60

P = 0.885*

GA/GG

P = 0.027*
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of sarcoidosis in these populations when the patient group
was evaluated as a whole. However, it was not associated
with sarcoidosis when the exclusion criterion was present,
which clinically and genetically represented a distinct
disease subset (14,15). Li et al. carried out a case-control
study including German patients, similar to the study by
Valentonyte et al. (9,16). According to their results, the
A allele is associated with an about 2-fold higher risk of
sarcoidosis in both a codominant and a dominant model,
but not in a recessive models. Another important study
performed by Milman et al. was added to the studies of
different ethnic groups (17). Their study comprising
Danish patients was significant in terms of ethnic data
and different levels of risk for sarcoidosis. The BTNL2 A
allele variant was very frequent in Danish patients with
sarcoidosis, and the AA genotype was associated with a
3.1-fold higher risk of sarcoidosis than the GG genotype.
Morais et al. evaluated the BTNL2 rs2076530 G/A allele
associations with sarcoidosis susceptibility in a Portuguese
population (18). Their data replicated the association of
BTNL2 rs2076530 A allele with sarcoidosis. In contrast to
Rybicki et al., a genome-wide association study conducted
in African-Americans showed that the A allele was
associated with higher risk of sarcoidosis (8,19). Suzuki
et al. performed a study in order to assess whether the
BTNL2 association was independently present in Japanese
patients with sarcoidosis (20). The BTNL2 rs2076530 A
allele was associated with an increased risk of sarcoidosis
(OR = 1.84) in their study, but the OR was lower than in
other ethnic groups.

In accordance with these results, our hypothesis was
that there might be a new variation around this mutation.
The 329-bp region was sequenced, but no variation was
found except the rs2076530 polymorphism in Turkish
patients with sarcoidosis. According to our results, there
was a significant association between the BTNL2 AA
genotype and sarcoidosis in Turkish patients. However, we
did not find a statistically significant difference when the
A allele frequency in the sarcoidosis group was compared
with the controls. In terms of the A allele frequency, we
observed a visible difference between sarcoidosis patients
and control subjects, but it did not indicate statistical
significance.
In conclusion, we found that the AA genotype was
associated with a 2.5-fold higher risk of sarcoidosis than
other genotypes in a recessive model. However, there was
no statistical difference in a dominant model. Milman
et al. reported that the AA genotype is associated with
an increased risk of sarcoidosis in both a dominant
and recessive model (17). Because of the sample size of
our study and difference in studied ethnic groups, our
results may have differed from theirs. The present study
has certain limitations in order to determine hereditary
characteristics but is important in terms of being the first
report in a Turkish population. Our results emphasize the
recessive characteristic of the rs2076530 polymorphism in
Turkish patients with sarcoidosis. The lack of any genetic
variation except rs2076530 in the 329-bp region is another
significant finding for Turkish patients.
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